Metformin systemic exposure

Metformin systemic exposure refers to the total amount of the drug metformin present in the systemic circulation, typically quantified by the area under the plasma concentration-time curve (AUC) (Source: PubChem). It is not a therapeutic target like a receptor or enzyme; instead, it is a pharmacokinetic parameter describing the drug's disposition in the body (Source: StatPearls). Metformin is a biguanide used to treat type 2 diabetes, and unlike many drugs, it does not undergo hepatic metabolism, being excreted unchanged in the urine (Source: FDA Label). The level of systemic exposure is governed by various transporters, specifically Organic Cation Transporter 1 (OCT1) for hepatic uptake and OCT2/MATE transporters for renal clearance (Source: PharmGKB). Elevated systemic exposure is a critical safety concern, particularly in patients with renal impairment, as it significantly increases the risk of metformin-associated lactic acidosis (MALA), a rare but potentially fatal condition (Source: PubMed, PMC4214042). Understanding the factors that influence metformin exposure, including genetic polymorphisms in SLC22A1 and SLC47A1, is essential for personalized dosing and minimizing adverse effects (Source: Clinical Pharmacology & Therapeutics).

Other names

Metformin plasma concentrationMetformin AUCMetformin pharmacokinetics

Not applicable. This term refers to a pharmacokinetic phenotype (the concentration of drug in the blood) rather than a molecular target or a drug's mechanism of action.